MARKET

STOK

STOK

Stoke Therapeutics
NASDAQ
31.93
-0.93
-2.83%
Closed 19:09 12/18 EST
OPEN
33.28
PREV CLOSE
32.86
HIGH
33.88
LOW
31.50
VOLUME
739.71K
TURNOVER
0
52 WEEK HIGH
38.69
52 WEEK LOW
5.35
MARKET CAP
1.82B
P/E (TTM)
48.38
1D
5D
1M
3M
1Y
5Y
1D
Stoke Therapeutics (STOK) Valuation After Positive Long-Term Zorevunersen Data at AES Meeting
Simply Wall St · 22h ago
Stoke Therapeutics Grants Stock Options to New Employees Under Inducement Plan
Reuters · 2d ago
STOKE THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 2d ago
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 2d ago
How Investors May Respond To Stoke Therapeutics (STOK) Data Suggesting Disease‑Modifying Potential In Dravet Syndrome
Simply Wall St · 3d ago
Stoke Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 3d ago
Stoke Therapeutics Price Target Raised to $50.00/Share From $35.00 by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Maintains Buy on Stoke Therapeutics, Raises Price Target to $50
Benzinga · 3d ago
More
About STOK
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Webull offers Stoke Therapeutics Inc stock information, including NASDAQ: STOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STOK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STOK stock methods without spending real money on the virtual paper trading platform.